Alnylam Pharmace. buy tbackenh
Summary
This prediction ended on 26.05.17 with a price of €59.62. The prediction had a final performance of 23.81%. tbackenh has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Alnylam Pharmace. | -2.422% | -2.422% | 31.617% | 37.717% |
iShares Core DAX® | 1.560% | 2.566% | 18.261% | 16.927% |
iShares Nasdaq 100 | 0.517% | 1.894% | 25.521% | 35.441% |
iShares Nikkei 225® | 1.730% | 5.631% | 18.569% | 13.063% |
iShares S&P 500 | 1.482% | 1.594% | 24.989% | 38.339% |
Comments by tbackenh for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylan Pharmaceutics
Sehr volatil, besonders zwischen 2012 bis 2015. Aktuell geht es wieder aufwärts, ich denke, dass aufgrund der Cashreserven noch was gehen könnte.